Bahador Bagheri

Dr. Bahador Bagheri

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2018 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
KNKhac-Dung Nguyen
Khac-Dung Nguyen
BBBahador Bagheri
Bahador Bagheri
HBHaleh Bagheri
Haleh Bagheri
Introduction: Drug-induced bone loss remains the major cause of vertebral and hip fractures and significantly associated to morbidity and mortality. This article will review the common drugs identified as the causes of bone loss and the risk factors and management in European countries. Areas covered: Beyond glucorticoid – the most cause of osteoporosis, many different drugs could cause harmful skeletal disorders. The antiepileptics, hormonal therapy, GnRH antagonists, aromatase inhibitors are well-known cause of bone loss. Osteoporosis and fractures risk also increased with calcineurin inhibitors, antiretroviral drugs, selective inhibitors of serotonin reuptake, loop diuretics, heparins, oral anticoagulants, high doses of thyroxine and proton pump inhibitors. Expert opinion: Drugs are an important secondary cause of osteoporosis. Healthcare professionals should reassess the requirement for drugs and use the lowest dosage and shortest duration. Lifestyle changes, adequate calcium, vitamin D supplement, appropriate monitoring of bone status and initiating osteoporosis treatment if indicated are recommended when drugs having potential deleterious effects on bone are used, particularly in high risk patients. The update and further studies would provide concluded evidences of controversial drugs induced bone loss and determine the best prevention and treatment strategies.

27 February 2024 in Mediators of Inflammation
Verified
Journal Article
Open access
BBBahador Bagheri
Bahador Bagheri
ZFZahra Khatibiyan Feyzabadi
Zahra Khatibiyan Feyzabadi
ANAhmad Nouri
Ahmad Nouri
AAAli Azadfallah
Ali Azadfallah
MAMahyar Mahdizade Ari
Mahyar Mahdizade Ari
SBSeyedeh Zahra Banihashemian
Seyedeh Zahra Banihashemian
Atherosclerosis is a leading cause of death in the world. A significant body of evidence suggests that inflammation and various players are implicated and have pivotal roles in the formation of atherosclerotic plaques. Toll-like receptor 4 (TLR4) is linked with different stages of atherosclerosis. This receptor is highly expressed in the endothelial cells (ECs) and atherosclerotic plaques. TLR4 activation can lead to the production of inflammatory cytokines and related responses. Lectin-like oxidized low-density lipoprotein-1 (LOX-1), an integral membrane glycoprotein with widespread expression on the ECs, is involved in atherosclerosis and has some common pathways with TLR4 in atherosclerotic lesions. In addition, proprotein convertase subtilisin/kexin type9 (PCSK9), which is a regulatory enzyme with different roles in cholesterol uptake, is implicated in atherosclerosis. At present, TLR4, PCSK9, and LOX-1 are increasingly acknowledged as key players in the pathogenesis of atherosclerotic cardiovascular diseases. Herein, we presented the current evidence on the structure, functions, and roles of TLR4, PCSK9, and LOX-1 in atherosclerosis.

13 October 2017 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
AEAziz Eghbali
Aziz Eghbali
HKHamideh Kazemi
Hamideh Kazemi
HTHassan Taherahmadi
Hassan Taherahmadi
YGYazdan Ghandi
Yazdan Ghandi
MRMohammad Rafiei
Mohammad Rafiei
BBBahador Bagheri
Bahador Bagheri

15 March 2014
Verified
Journal Article
Open access
AEA Eghbali
A Eghbali
HTH Taherahmadi
H Taherahmadi
MSM Shahbazi
M Shahbazi
BBBahador Bagheri
Bahador Bagheri
LEL Ebrahimi
L Ebrahimi
Frequent blood transfusion is often associated with iron overload. Proper use of iron chelators to treat iron overload requires an accurate measurement of iron levels. Magnetic resonance T2-star (T2* MRI) can measure iron level in the heart and liver. Our goal was to see whether an association exists between serum ferritin level and T2* MRI in patients with major beta thalassemia. Sixty patients with a diagnosis of major beta thalassemia were enrolled in the study. They were older than five years old and needed regular transfusion. Cardiac and hepatic T2*MRI and mean serum ferritin levels were measured within 3 months. No significant correlation was observed between serum ferritin level and cardiac T2*MRI (p=0.361, r=-0.120).However, a significant correlation was observed between serum ferritin and liver T2*MRI (p=0.021, r=-0.297). Our results showed an association between hepatic T2*MRI and serum ferritin level.

1 August 2016 in Haemophilia
Verified
Journal Article
Closed access
PDF file
AEA. Eghbali
A. Eghbali
LML. Melikof
L. Melikof
HTH. Taherahmadi
H. Taherahmadi
BBBahador Bagheri
Bahador Bagheri

23 April 2019 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
PDF file
AEAziz Eghbali
Aziz Eghbali
PSPooria Shokri
Pooria Shokri
RARoghayeh Rahimi Afzal
Roghayeh Rahimi Afzal
BBBahador Bagheri
Bahador Bagheri